modelCefiximeAndBetaLactamase
Extends from Pharmacolibrary.Drugs.ATC.J.J01DD58.
Information
| name: | CefiximeAndBetaLactamaseInhibitor | |
| ATC code: | J01DD58 | route: | oral |
| compartments: | 1 | |
| dosage: | 400 | mg |
| volume of distribution: | 17 | L |
| clearance: | 3 | L/h |
| other parameters in model implementation | ||
Cefixime is a third-generation oral cephalosporin antibiotic used to treat a range of bacterial infections, including respiratory tract, urinary tract, and sexually transmitted infections. Beta-lactamase inhibitors are agents that extend the spectrum of beta-lactam antibiotics by inhibiting beta-lactamase enzymes produced by bacteria, which would otherwise degrade the antibiotic. The fixed-dose combination of cefixime and a beta-lactamase inhibitor is intended to overcome resistance in beta-lactamase-producing organisms. As of now, such fixed-dose combinations are used in some countries but are not broadly approved in the US/Europe.
Pharmacokinetics
Estimated pharmacokinetic parameters for the combination product (cefixime and beta-lactamase inhibitor) in healthy adults, based on known PK of cefixime and class properties of oral beta-lactamase inhibitors.
References
Birgy, A, et al., & Bonacorsi, S (2021). Clavulanate combinations with mecillinam, cefixime or cefpodoxime against ESBL-producing Enterobacterales frequently associated with blaOXA-1 in a paediatric population with febrile urinary tract infections. The Journal of antimicrobial chemotherapy 76(11) 2839–2846. DOI:10.1093/jac/dkab289 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34453533
Koeth, LM, et al., & Saunders, KA (2004). Comparative in vitro activity of a pharmacokinetically enhanced oral formulation of amoxicillin/clavulanic acid (2000/125 mg twice daily) against 9172 respiratory isolates collected worldwide in 2000. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 8(6) 362–373. DOI:10.1016/j.ijid.2004.02.005 PUBMED:https://pubmed.ncbi.nlm.nih.gov/15494258
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)